PharmGen Science, Inc. (004720) Price & Analysis

004720 Stock Chart & Stats

₩2,765.00₩15.00(0.55%)

At close: Oct 30 4:00 PM EDT

Day’s Range: KRW 2,735.00 - KRW 2,815.00
52-Week Range: KRW 2,590.00 - KRW 4,485.00
Previous Close: KRW 2,750.00
Volume: N/A
Average Volume (3M): 14.50K
Market Cap: KRW 62.52B
Enterprise Value: KRW 45.24B
Total Cash (Recent Filing): KRW 20.05B
Total Debt (Recent Filing): KRW 698.13M
Price to Earnings (P/E): ―
Beta: -0.04
Next Earnings: Nov 18, 2026
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Conservative Leverage

Very low leverage gives PharmGen Science financial flexibility while reducing balance-sheet pressure during periods of weak profitability. A substantial equity and asset base can help the company absorb operating shocks and preserve capacity to fund development or other strategic needs.

Improved Cash Generation

The sharp TTM recovery in operating and free cash flow demonstrates that the business has recently generated meaningful cash despite reported losses. If sustained, this improvement can support ongoing operations and investment without relying as heavily on additional borrowing or equity funding.

Strong Gross Margins

Gross margins in the low-to-mid 60% range indicate that PharmGen Science retains meaningful economics at the product level. This provides a foundation for future operating improvement if the company can control below-the-line pressures and convert gross profit into more consistent earnings.

Bears Say

Severe Net Losses

The shift from positive earnings to very large net losses materially weakens earnings quality and makes profitability difficult to underwrite. Even with positive EBIT and EBITDA margins, deeply negative net margins can consume equity value and constrain internally funded investment over the next several quarters.

Inconsistent Cash Flow

Repeated periods of negative operating or free cash flow show that recent cash improvement has not yet established a dependable multi-year pattern. This inconsistency can complicate budgeting, reduce funding certainty for research and commercialization, and increase reliance on balance-sheet resources when conditions weaken.

Limited Revenue Growth

Only modest TTM revenue growth limits the company’s ability to absorb fixed costs and offset the impact of large below-the-line losses. Without stronger and more durable sales expansion, PharmGen Science may struggle to improve operating leverage and translate its healthy gross margins into stable profits.

004720 FAQ

What was PharmGen Science, Inc.’s price range in the past 12 months?

PharmGen Science, Inc. lowest stock price was ₩2590.00 and its highest was ₩4485.00 in the past 12 months.

What is PharmGen Science, Inc.’s market cap?

PharmGen Science, Inc.’s market cap is ₩62.52B.

When is PharmGen Science, Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were PharmGen Science, Inc.’s earnings last quarter?

PharmGen Science, Inc. released its earnings results on Aug 14, 2026. The company reported -₩614 earnings per share for the quarter.

Is PharmGen Science, Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does PharmGen Science, Inc. pay dividends?

PharmGen Science, Inc. does not currently pay dividends.

What is PharmGen Science, Inc.’s EPS estimate?

PharmGen Science, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does PharmGen Science, Inc. have?

PharmGen Science, Inc. has 22,654,366 shares outstanding.

What happened to PharmGen Science, Inc.’s price movement after its last earnings report?

PharmGen Science, Inc. reported an EPS of -₩614 in its last earnings report. Following the earnings report the stock price went up 2.64%.

Which hedge fund is a major shareholder of PharmGen Science, Inc.?

Currently, no hedge funds are holding shares in KR:004720

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description